Angiotensin II and COVID-19. Secrets of interactions

Angiotensin II and COVID-19. Secrets of interactions

The article describes current data on the relationship of renin-angiotensin system and related drugs with the risk of COVID-19 infection and its outcomes. Analysis of the latest publications did not reveal association of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers w...

Full description

Bibliographic Details
Main Authors:	A. O. Konradi, A. O. Nedoshivin
Format:	Article
Language:	Russian
Published:	«FIRMA «SILICEA» LLC 2020-05-01
Series:	Российский кардиологический журнал
Subjects:	covid-19 angiotensin converting enzyme inhibitors angiotensin converting enzyme 2
Online Access:	https://russjcardiol.elpub.ru/jour/article/view/3861

Similar Items

Antecedent Administration of Angiotensin‐Converting Enzyme Inhibitors or Angiotensin II Receptor Antagonists and Survival After Hospitalization for COVID‐19 Syndrome
by: Alberto Palazzuoli, et al.
Published: (2020-11-01)

Angiotensin converting enzyme inhibitors /
by: DeBrue, Anne N.
Published: (c200)

No harm from angiotensin-converting enzyme inhibitors or angiotensin receptor inhibitors in patients with COVID-19. Results of a prospective study on a hospital-based cohort
by: Gian Paolo Anzola, et al.
Published: (2020-09-01)

Serum angiotensin converting enzyme in pemphigus vulgaris
by: Reza M Robati, et al.
Published: (2014-01-01)

Investigating the Relationship Between High Levels of Angiotensin II in Plasma and the Rate of Deterioration in Hypertensive Patients to COVID-19
by: Mina Shahnazari, et al.
Published: (2023-03-01)

Association of Angiotensin‐Converting Enzyme Inhibitors and Angiotensin Receptor Blockers With the Risk of Hospitalization and Death in Hypertensive Patients With COVID‐19
by: Rohan Khera, et al.
Published: (2021-07-01)

A study of prognosis and outcome of COVID-19-infected hypertensive patients on angiotensin-converting enzyme inhibitors/angiotensin receptor blockers
by: M S Bharath, et al.
Published: (2024-01-01)

Angiotensin-converting Enzyme Inhibitors: Can it be a Potential Treatment of Infantile Hemangioma
by: Archika Gupta, et al.
Published: (2021-01-01)

Clinical outcomes of COVID-19 following the use of angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers among patients with hypertension in Korea: a nationwide study
by: Ju Hwan Kim, et al.
Published: (2020-12-01)

Relating angiotensin‐converting enzyme inhibitors or angiotensin receptor blockers with incidence or mortality of COVID‐19
by: Martin C.S. Wong, et al.
Published: (2020-10-01)

The role of renin-angiotensin system and angiotensin-converting enzyme 2 (ACE2) in the development and course of viral infection COVID-19 in patients with diabetes mellitus
by: O. K. Vikulova, et al.
Published: (2020-08-01)

Angiotensin‐Converting Enzyme Inhibitors or Angiotensin Receptor Blockers Use and COVID‐19 Infection Among 824 650 Patients With Hypertension From a US Integrated Healthcare System
by: Jaejin An, et al.
Published: (2021-02-01)

Influence of angiotensin converting enzyme inhibitors/angiotensin receptor blockers on the risk of all‐cause mortality and other clinical outcomes in patients with confirmed COVID‐19: A systemic review and meta‐analysis
by: Na Jia, et al.
Published: (2021-09-01)

COVID-19 morbidity and mortality associated with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers use among 14,129 patients with hypertension from a US integrated healthcare system
by: Jaejin An, et al.
Published: (2021-06-01)

Angiotensin II Promotes SARS-CoV-2 Infection via Upregulation of ACE2 in Human Bronchial Cells
by: Ilaria Caputo, et al.
Published: (2022-05-01)

Management of hypertension in patients with COVID-19: Implication of angiotensin-converting enzyme 2
by: Guang-Hong Jia, et al.
Published: (2021-01-01)

Postoperative angioedema induced by angiotensin-converting enzyme inhibitor: case report
by: Flora Margarida Barra Bisinotto, et al.
Published: (2019-12-01)

Local Angiotensin-Converting Enzyme 2 Gene Expression in Kidney Allografts Is Not Affected by Renin-Angiotensin-Aldosterone Inhibitors
by: Monika Cahova, et al.
Published: (2021-03-01)

Renin–Angiotensin–Aldosterone System Inhibitors in Patients with COVID-19: General Considerations and Clinical Implications
by: Neiberg de Alcantara Lima, et al.
Published: (2020-05-01)

Renin–Angiotensin–Aldosterone System Inhibitors in Patients with COVID-19: General Considerations and Clinical Implications
by: Neiberg de Alcantara Lima, et al.
Published: (2020-05-01)

Renin–Angiotensin–Aldosterone System Inhibitors in Patients with COVID-19: General Considerations and Clinical Implications
by: Neiberg de Alcantara Lima, et al.
Published: (2020-05-01)

Renin–Angiotensin–Aldosterone System Inhibitors in Patients with COVID-19: General Considerations and Clinical Implications
by: Neiberg de Alcantara Lima, et al.
Published: (2020-06-01)

Nutritional composition and angiotensin-converting enzyme inhibitory activity of blue lupin (Lupinus angustifolius L.)
by: Chin, Ying Yee
Published: (2017)

Effect of angiotensin converting enzyme inhibitor and angiotensin II receptor blocker on the patients with sepsis
by: Hyun Woo Lee, et al.
Published: (2021-03-01)

Reply to Siniorakis et al., “COVID-19 Interference with Renin-Angiotensin System in the Context of Heart Failure”
by: David S. Fedson, et al.
Published: (2020-06-01)

The Role of ACE, ACE2, and AGTR2 Polymorphisms in COVID-19 Severity and the Presence of COVID-19-Related Retinopathy
by: Kristina Jevnikar, et al.
Published: (2022-06-01)

2019 novel-coronavirus: Cardiovascular insights about risk factors, myocardial injury, therapy and clinical implications
by: Luigi Cappannoli, et al.
Published: (2020-12-01)

The Angiotensin Converting Enzyme Deletion/Deletion Genotype Is a Risk Factor for Severe COVID-19: Implication and Utility for Patients Admitted to Emergency Department
by: Anna Annunziata, et al.
Published: (2021-08-01)

Treatment of Patients with COVID-19 and Concomitant Cardiovascular Diseases: Do not Forget About the Principles of Evidence-based Medicine
by: S. Yu. Martsevich
Published: (2020-05-01)

A continuous fluorescent assay for the determination of plasma and tissue angiotensin I-converting enzyme activity
by: M.F. Alves, et al.
Published: (2005-06-01)

Administration of Tranexamic Acid as Treatment for Angiotensin Converting Enzyme Inhibitor-Induced Angioedema: A Case Report
by: Sohun Awsare, et al.
Published: (2021-07-01)

Clinical outcome of renin-angiotensin-aldosterone system blockers in treatment of hypertensive patients with COVID-19: a systematic review and meta-analysis
by: Andrea Laurentius, et al.
Published: (2021-02-01)

Effect of an angiotensin-converting-enzyme inhibitor on the plasma concentration of cytokines and vasoactive molecules in patients with coronary heart disease and hypertension
by: A A Khadartsev, et al.
Published: (2017-12-01)

Angiotensin-Converting Enzyme Inhibitor / Angiotensin II Receptor Blocker in COVID-19: a Double-edged Sword or a Myth
by: Kunal Bikram Shaha, et al.
Published: (2020-05-01)

Gene polymorphisms of angiotensin-converting enzyme, angiotensin type 1 receptor and ⁪⁯α-adducin associated with renin angiotensin-aldosterone system in Malaysian end-stage renal disease patients
by: Ali, Aisyah
Published: (2012)

Hypertension, renin-angiotensin-aldosterone-system-blocking agents, and COVID-19
by: Si-Hyuck Kang, et al.
Published: (2021-06-01)

Renin-angiotensin system modulators and other risk factors in COVID-19 patients with hypertension: a Korean perspective
by: Hee-Sung Kim, et al.
Published: (2021-02-01)

RENIN-ANGIOTENSIN SYSTEM IN REGULATION OF HEMATOPOIESIS
by: M. L. Kanaeva, et al.
Published: (2018-02-01)

Medicinal chemistry of the renin-angiotensin system /
by: Timmermans, P. B. M. W. M., et al.
Published: (1994)

Evaluation of the Association between Multilobar Involvement and ACE Inhibitor Use in SARS-CoV-2 Patients
by: Dilay Satilmis, et al.
Published: (2023-01-01)